Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

被引：16

作者：

Zhang, Haozhe ^{[1
]}

Zhou, Yi ^{[1
]}

Xing, Zengzhen ^{[1
]}

Sah, Rajiv Kumar ^{[1
]}

Hu, Junqi ^{[1
]}

Hu, Hailiang ^{[1
,2
]}

机构：

[1] So Univ Sci & Technol, Sch Med, Dept Biochem, Shenzhen 518055, Peoples R China

[2] Southern Univ Sci & Technol, Key Univ Lab Metab & Hlth Guangdong, Shenzhen 518055, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 21期

基金：

中国国家自然科学基金;

关键词：

androgen metabolism; androgen receptor; anti-androgen therapy; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; UDP-GLUCURONOSYLTRANSFERASES; INDEPENDENT GROWTH; CYP17A1; INHIBITION; BACKDOOR PATHWAY; RECEPTOR; CASTRATION; TESTOSTERONE; ABIRATERONE; EXPRESSION;

D O I：

10.3390/ijms232113521

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

All aspects of prostate cancer evolution are closely related to androgen levels and the status of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways and AR, from castration-sensitive prostate cancer (CSPC) to castration-resistant prostate cancer (CRPC). Alterations in androgen metabolism and its response are one of the main reasons for prostate cancer drug resistance. In this review, we will introduce androgen metabolism, including how the androgen was synthesized, consumed, and responded to in healthy people and prostate cancer patients, and discuss how these alterations in androgen metabolism contribute to the resistance to anti-androgen therapy.

引用

页数：15

共 50 条

[31] Prostate cancer risk after anti-androgen treatment for priapism
Tabitha Goetz
Arthur L. Burnett
International Urology and Nephrology, 2014, 46 : 757 - 760
[32] Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.
Sharifi, Nima
Li, Zhenfei
Alyamani, Mohammad
Li, Jianneng
Upadhyay, Sunil
Balk, Steven P.
Taplin, Mary-Ellen
Auchus, Richard J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Prostate cancer risk after anti-androgen treatment for priapism
Goetz, Tabitha
Burnett, Arthur L.
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (04) : 757 - 760
[34] ANTI-ANDROGEN THERAPY IN DERMATOLOGY - REVIEW
BURTON, JL
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1979, 4 (04) : 501 - 507
[35] Targeting anti-androgen therapy resistance through epigenetic rewiring
Dunmore, Kate E.
Rickman, David S.
NATURE CANCER, 2025, : 564 - 566
[36] Comparison of longitudinal changes in BMD in advanced prostate cancer patients treated with androgen ablation or anti-androgen hormonal therapy
Hussain, A
Wadhwa, V
Weston, R
Parr, N
George, E
RHEUMATOLOGY, 2005, 44 : I7 - I8
[37] Aryl Hydrocarbon Receptor Signaling in Prostate Cancer Therapy: A Review of Implications for Anti-androgen Treatment Strategies and Resistance
Singh, Gurjot
Trehan, Shubam
Singh, Adarshpreet
Goswami, Kanishka
Farooq, Amna
Antil, Priya
Puri, Piyush
Bector, Gaurav
Jain, Aayush
Azhar, Waqas
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
[38] Intermittent anti-androgen monotherapy: a possible treatment for androgen receptor-overexpressing prostate cancer
Oliver, Tim
Berney, Dan
Shaw, Greg
CANCER RESEARCH, 2015, 75
[39] CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer
Liang, Hai-qi
He, Qi-huan
Wei, Qiu-ju
Mo, Qi-zhou
Yang, Guang-lin
Wei, Fa-ye
Wei, Li-wei
Li, Yu-jian
Qin, Min
Cheng, Ji-wen
GENES & GENOMICS, 2025,
[40] Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
Zhang, Keke
Yan, Fei
Lei, Xiaoying
Wei, Di
Lu, Huanyu
Zhu, Zheng
Xiang, An
Ye, Zichen
Wang, Li
Zheng, Wanxiang
Li, Xi'an
Yuan, Jiarui
Lu, Zifan
Yuan, Jianlin
MOLECULAR MEDICINE REPORTS, 2018, 17 (06) : 8203 - 8211

← 1 2 3 4 5 →